Heartseed (219A) · InitiativeRestated
Improving iPS cell production and differentiation efficiency with H1foo
First written in FY2024. 1 of 2 entries say "Restated". Latest entry: FY2025.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Improving iPS cell production and differentiation efficiency with H1fooA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「We address this issue by adding the quality-enhancing agent H1foo when introducing reprogramming factors to reprogram ordinary cells into iPS cells, and the Company exclusively owns the intellectual property relating to this research.」
The Company continues to describe its H1foo technology, which improves the efficiency of establishing high-quality iPS cells and cardiomyocyte differentiation, as a candidate for applications including personalized treatment. - FY2024First statedAnnual report
「We address this issue by adding the quality-enhancing agent H1foo when introducing reprogramming factors, and the Company exclusively owns the intellectual property relating to this research.」
H1foo is used to improve variability in iPS cell establishment quality and cardiomyocyte differentiation efficiency, with potential applications including personalized treatment.